A Key Clinical Message
Multidisciplinary treatment enabled the patient with stage IVB intrahepatic cholangiocarcinoma to achieve long-term survival although specific side effects of pemigatinib (nail disorders, hyperphosphatemia, and taste disorders) was appeared.
Keywords: pemigatinib, intrahepatic cholangiocarcinoma, fibroblast growth factor receptor 2, comprehensive genomic profiling